Article

Researchers make great strides under Artificial Retina Project

Researchers are developing nano-sized implantable electronic devices, positioned either on the surface or under the retina, which would stimulate the neuroretinal cells of individuals with damaged retinas.

Key Points

The notion of an artificial retina that would bring the gift of sight to individuals whose retinas have been destroyed or damaged through trauma or disease seems so outlandish that, until recently, it was hard to believe that such whimsy might be taken seriously. Yet that concept is the center of a massive government effort, bringing together several government labs, private companies, and public and private universities.

The overall guiding force for those investigations is the Artificial Retina Project, a scientific consortium under the auspices of the Department of Energy. The effort takes in several well-known public/private organizations, including the Sandia, Argonne, Oak Ridge, Los Alamos, Brookhaven, and Lawrence Livermore national laboratories, as well as several universities and private companies. Large cooperative programs of this nature are becoming common in biological research because investigators struggle with problems of increasing complexity, including systems biology, mapping of neuronal pathways in the central nervous system, and, of course, the human genome and proteome projects. Two decades ago, monster scientific ventures were virtually unknown in biology, and the concept of employing huge umbrella organizations in basic research was confined to fields such as particle physics and space exploration.

Artificial Retina Project

The goals of the Artificial Retina Project, along with a group of companies and research teams, are much grander, hinging on the construction of nano-sized implantable devices that would be attached to damaged retinas of individuals who had lost all or almost all of their visual capability. Two possible orientations of those devices are under investigation.

What enables the technology to work is the discovery that optical neurons in the retina still are capable of transmitting signals even when the sensory cells of the retina are destroyed. Thus an electrode-studded array tacked to the retina can activate the optical neurons. The apparatus consists of a miniaturized camera and microprocessor mounted in a pair of glasses, which transmits to a receiver behind the ear. Power emanates from a battery pack mounted on a belt.

Those "Borg"-like inventions raise profound philosophical, ethical, and scientific questions. Individuals whose personalities were defined by life-long blindness can regain some vision and the ability to cope with a world designed for sighted individuals. The Doheny Eye Institute, Los Angeles, one of the participants in the Artificial Retina Project, has evaluated its simplest model with 16 electrodes on several patients and soon will introduce an improved version with 60 electrodes on a new group of volunteers.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.